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ABSTRACT 
The purpose of the current research was to determine if diabetes had a significant 
effect on the healing process of an injury caused by bacteria, and to identify the potential 
mechanisms involved. To achieve the objective of the study, diabetic mice and 
normoglycemic mice (n=6) were inoculated with Porphyromonas gingivalis (P. gingivalis). 
Scalp tissue was excised eight days later, and either fixed for histological sections or snap 
frozen for molecular analysis. Histological analysis from the inoculated site revealed that 
diabetes increased apoptosis of fibroblast and bone lining cells when compared to 
normoglycemic animals (p<0.05; n=6). When the pancaspase inhibitor z-V AD-fink (N-
benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) was used to inhibit diabetes-enhanced 
apoptosis, several parameters of healing, including fibroblast density and ir.tcreased matrix 
formation were observed. Total RNA from the excised scalp tissue obtained from 
normoglycemic (n=6) and diabetic (n=6) was subjected to RNA profiling, using a Mouse 
Genome 430 2.0 Array to determine how diabetes affects the global expression of various 
genes involved in wound healing. The microarray analysis revealed that out of 221 
differentially expressed apoptotic genes; diabetes caused more than a twofold induction of 71 
genes that directly or indirectly regulate apoptosis. Most of the healing, angiogenesis, growth 
factor, matrix and immune response genes are highly expressed at 5 days but there is only a 
moderate increase at 8 days signifying that early defense and wound healing process initiated 
at 5 days and almost completed at 8 days. Therefore, it was inferred that day 5 is important 
to study wound healing. And also diabetes-enhanced apoptosis is an important mechanism 
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that could affect delayed wound healing. This particular process can be partially clarified by 
diabetes-increased expression of pro-apoptotic genes. 
XIX 
INTRODUCTION 
1.1 Bioinformatics 
1.1.1 Introduction and Definition 
The current study primarily employs a bioinformatics approach by using microarray 
analysis to determine the effect of diabetes on altering the mRNA levels of the potential genes 
that could contribute to impaired wound healing. Bioinformatics is more commonly described as 
"the use of information theory, computer science, and mathematics to model and analyze 
biological systems" (Xiong 2006). From various definitions in the literature with regard to 
bioinformatics, the most widely accepted explanation is that it is the science of informatics as 
applied to biological research (Baxevanis and Ouellette 2005). The term, informatics, essentially 
refers to "the analysis and management of large amounts of complex data using advanced 
computing techniques" (Baldi 2001 ). Bioinformatics conceptualizes biology in terms of 
molecules, and applies informatics techniques derived from disciplines such as applied 
mathematics, computer science, and statistics to understand and organize the information 
associated with these molecules on a large scale. In short, bioinformatics is "the management 
information system for molecular biology" (Luscombe, Greenbaum et al. 2001). 
Bioinformatics application platforms have become indispensable in life science analysis, 
as the increasing volume of complex biological data collected in recent years has prompted 
increased demand for bioinformatics tools, especially for genomic and proteomic data analysis 
(Quo, Wu et al. 2005). Such designations as "bioinformatics" and "computational biology" are 
used quite frequently, but bioinformatics differs in the sense that it specifically refers to 
computational and statistical techniques, advanced algorithms, and use of theory to answer 
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problems associated with biological data analysis and management (Baxevanis, Davison et al. 
2002). However, computational biology coincides more with systems biology, and uses 
hypotheses and experimental data to investigate a specific biological problem using computers. 
Both bioinformatics and computational biology platforms uses mathematical tools to analyze 
biological data to resolve research questions. Techniques involved in bioinformatics and 
computational biology include the use of chemistry, biochemistry, applied mathematics, and 
computer science to solve biological problems on a molecular level. 
1.1.2 Applications and Perspectives of Bioinformatics 
According to the Bioinformatics Resource Portal, bioinformatics has a number of 
applications. These include molecular and preventative medicine, gene study and gene therapy, 
drug development, biotechnology, antibiotic resistance, forensic analysis of microbes, microbial 
genome applications, evolutionary studies, mass spectrometry, and microarray analysis. 
Important research efforts in the field of bioinformatics include novel gene identification, 
sequence alignment, protein structure alignment, protein interactions, and genome assembly 
(Baxevanis and Ouellette 2005). The current investigation attempts to identify a biologically 
specific and significant relationship between the state of diabetes and altered gene expression, 
responsible for the delayed wound healing seen in diabetics. The study utilizes a microarray 
analysis approach, followed by a bioinformatics data mining process. 
1.1.3 Microarray 
Microarray technology originated under the hypothesis that hybridization between 
nucleic acids (a sequence of which is immo~ilized on a substrate) provides high sensitivity and 
specificity of detection between complementary strands of nucleic acids (Southern, Mir et al. 
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1999). Microarray combines standard molecular techniques with high throughput screemng, 
which can be achieved in a single experiment (Goldsmith and Dhanasekaran 2004). Before the 
discovery of microarray, work was completed in a linear fashion. First, genes or proteins were 
sequentially identified, and then their functions were characterized within the model system. This 
approach was tedious and slow. However microarray technique significantly improved this 
process by identifying genes that are altered in a real time screen of the entire genome 
(Goldsmith and Dhanasekaran 2004). 
The appeal of this technology, according to Bier and Kleinjung, is its ability to assist with 
large-scale parallel determinations of many factors, all at the same time. Instead of studying one 
gene at a time, as been the tradition in the past, microarrays allow the researcher to analyze 
thousands of genes at the same time significantly reducing time and labor-intensive analytic 
efforts (Bier and Kleinjung 2001). Microarray consists of thousands of cDNA strands, or 
oligonucleotide sequences, attached to a substrate (usually a glass slide or a nylon membrane). 
The immobilized sequences are referred to as "probes." Each probe corresponds to a "gene," 
irrespective of whether it actually represents a gene of full length, an expressed sequence tag, or 
DNA from other sources (Hegde, Qi et al. 2000). The relative abundance of each of the gene-
specific sequences in RNA samples (test and reference) may be estimated by fluorescently 
labeling the samples and hybridizing the mixture to the sequences on the glass slide. The samples 
of mRNA from cells or tissue (target) are reverse transcribed into cDNA, and labeled using 
fluorescent dyes (such as red Cy5 and green Cy3, in general). The mixture reacts with the spotted 
cDNA sequences (probes). This step, called oligo-hybridization, results in cDNA sequences from 
the targets and probes base-pairing with one another. After this hybridization step is complete, 
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the m1croarray is placed in a scanner, consisting of lasers with different wavelengths, a 
microscope, and a camera. The slide is scanned with laser light, which excites the fluorescent 
dyes (Cy3 is excited by green laser light such as 532nm; Cy5 is excited by red laser light at 
635nm). The dyes emit fluorescent radiation with characteristic spectra, which is measured by 
the microscope and camera to create monochrome digital images of the array (Hegde, Qi et al. 
2000). In summary, microarray has the capability to quickly generate multiple gene expression 
profiles in parallel. Thus, it can be used in many different types of experiments, particularly 
those relating to disease, which is the focus of the present investigative study. 
1.1.4 Array Assist Software 
After the successful completion of any microarray experiment, the gene expression value 
comes in the form of raw electronic files, which are usually proprietary to various gene chip 
manufacturers such as .CEL. These electronic files are processed by free commercial software 
for various control features to make the inter-experiment variance minimal. In this study, we 
used ArrayAssist software (Stratagene Software Solutions, La Jolla, CA) to normalize the raw 
expression values, based on various probe sets representing each specific gene. Themeau and 
Ballman (2004) introduced an algorithm called the probe logarithmic intensity error (PLIER) 
algorithm, developed in 2004 by Affymetrix. Probe logarithmic intensity error estimation was 
used to determine the relative influence of vaiious probe sets for each gene, in order to achieve a 
final expression value for that gene. The basic principle behind the probe logarithmic intensity 
error estimation algorithm is that it produces a summary value for a probe set-that is, an 
improved gene expression value for the GeneChip microarray platform. The researchers' report 
further explains that PLIER uses a probe affinity parameter. This parameter signifies the strength 
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of a signal that is produced at a specific concentration for the given probe in question. "The 
probe affinities are calculated using data across arrays. The error model employed by PLIER 
assumes that error is proportional to observed intensity, rather than to background-subtracted 
intensity" (Themeau and Ballman). 
In conclusion, the PLIER algorithm yields improved estimations of the expression values 
for low RNA concentration levels for the given GeneChip microarray. The PLIER algorithm 
outperforms other algorithm methods like MASS, RMA that are widely used for computing the 
gene expression values for a given GeneChip probe set data (Cope, Irizarry et al. 2004; Irizarry, 
Wu et al. 2006). The PLIER algorithm expects to improve the background binding with a better 
estimated (Naef and Magnasco 2003) interpretation of intensities, handles error appropriately 
across low and high target abundance, and rejects outliers (Naef and Magnasco 2003; Cope, 
Hartman et al. 2006). The main goal of any microarray experiment is to identify differentially 
expressed genes. It is considered practical to follow up only a limited number of biologically 
significant genes to identify the most likely candidates and scientifically more fruitful to focus on 
genes that are functionally related (Stum, Quackenbush et al. 2002). 
1.1.5 Pathway Architect Software and Bioinformatics Databases 
Different databases were normally used to analyze genes, including the database of 
interacting protein (DIP), biomolecular interaction network database (BIND), kyoto 
encyclopedia of genes and genomes (KEGG), and gene ontology (GO). Pathway Architect is a 
software package provided by the Iobion Company located in La Jolla, CA. In the present study, 
Pathway Architect software was identified to be very user-friendly and straightforward to use. 
The software uses LocusLink IDs as the gene identifier, to derive the relationship of the raw 
5 
expression value and fold difference between groups to annotated biological · pathways. Pathway 
Architect provides simultaneous visualization of the expression data on a pathway diagram. In 
addition, Pathway Architect can easily import annotated pathway information, along with the 
biological functions of various known genes from the Biomolecular interaction network database 
and the database of interacting proteins. In more recent years, these comprehensive databases 
have been merged and combined with analytical and network building tools. The resulting 
products have been the creations of data mining suites such as Pathway Architect 
(http://wv,,r\v.ariadnegenomics.com), PathArt (http://jubilantbiosys.corn), MetaCore 
(http://www.genego.com), and Pathways Analysis (http://w\vw.ingenuitv.com/), among others 
(Ekins, Nikolsky et al. 2005). 
1.2 Diabetes Mellitus 
1.2.1 Introduction 
Diabetes is a metabolic disease that affects more than 5% of world's population. It has 
high morbidity and mortality rates due to its complications such as nephropathy, retinopathy, 
neuropathy, and atherosclerosis (Kasuga 2006). The total number of people with diabetes 
worldwide was estimated at between 151 million and 171 million in 2000, is projected to 
increase to 221 million in 2010, and to 366 million in 2030 (Kasuga 2006). Diabetes poses a 
huge medical and economic burden for both the developing as well as the developed world. The 
cost of medical care associated with diabetes and its complications exceeds $132 billion annually 
(ADA 2004). Diabetes currently has no cure, but early detection and preventive efforts, including 
lifestyle modifications and medication, may serve to control the disease and reduce some of its 
life-threatening complications (Turkoski 2006). 
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1.2.2 Classification 
Both the World Health Organization and the American Diabetes Association committees 
agreed to adopt a common etiological classification and share unified terminology (Alberti and 
Zimmet 1998). They suggested that the terms "insulin-dependent diabetes mellitus" and "non-
insulin-dependent diabetes mellitus," be replaced with type I and type 2, with an emphasis on 
using Arabic rather than Roman numerals. The etiological type, named type I, includes the 
majority of cases that are primarily due to pancreatic islet /3-cell destruction, and are prone to 
ketoacidosis. This sub-type also includes cases attributable to an autoimmune process, as well as 
those prone to ketoacidosis, in which /3-cell destruction is of uncertain etiology (idiopathic). 
Forms of /3-cell destruction or failure where specific causes can be identified are now classified 
as Other Specific Types. 
Type I (B cell destruction) includes Autoimmune and idiopathic. Autoimmune is also called 
clinically slowly progressive type I diabetes. 
Type II 
Ranging from a predominantly insulin resistance to a predominantly secretory defect, with or 
without insulin resistance. Insulin resistance, excessive glucose production by liver and 
inadequate insulin production to compensate for insulin resistance. "Other forms of diabetes" 
include genetic defects of /3 cell function ( e.g., MODY 1-3), mitochondrial DNA, genetic defects 
in insulin action ( e.g., type A insulin resistance), diseases of the exocrine pancreas, 
endocrinopathies, drug or chemical-induced; infectious ( e.g., congenital rubella), uncommon 
forms of immune-mediated diabetes (e.g., "stiff man" syndrome), and other genetic syndromes, 
sometimes associated with diabetes gestational hyperglycemia. 
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1.2.3 Type I Diabetes 
Type I diabetes occurs when the body produces little or no insulin, because {3 cells in the 
pancreas have been destroyed by either idiopathic or autoimmune processes (Genuth 1997). The 
autoimmune cases have varying rates of B cell destruction, and present with various autoimmune 
antibodies against islet cells and insulin. Clinical symptoms such as polyuria, polydipsia, and 
weight loss are observed after the disease has been undetected for a period of time. Type I 
diabetes is generally juvenile in onset, and must be treated throughout the remainder of the 
patient's life. Treatment typically consists of maintaining a sufficient insulin level by its 
exogenous administration, to maintain an optimal glycemic level (Porth 2006). It is important to 
understand that when the transportation of glucose into the cells is not facilitated with insulin, the 
source of energy for the metabolism shifts from carbohydrates to lipids. The shift of the 
metabolism to predominantly lipid-based energy leads to an increase in ketoacids, which 
subsequently results in metabolic acidosis (Turkoski 2006). This ketoacidosis only occurs in 
extreme cases of uncontrolled diabetes. If this is not treated, it can eventually result in coma and 
death (Turkoski 2006). 
1.2.4 Type II Diabetes 
Type II diabetes widely affects the larger population of those who have been diagnosed 
with diabetes. Specifically, about 90% of those diagnosed with diabetes are affected by type II 
diabetes (Miranda, DeFronzo et al. 2005). Type II diabetes increased by 33% in the years 
between 1990 and 1998. Type II is a more silent form of diabetes than type I, because it does not 
give classic warning signs or acute hyperglycemic episodes (Muggeo 1998). Type II diabetes is 
8 
mostly seen in populations aged 30 years or older, and is often called adult-onset diabetes. This 
diabetes is most often related to obesity (Bray and Bellanger 2006). This form of diabetes is 
often amenable to controlled diet, weight loss, and exercise. When lifestyle changes are not 
completely effective, oral antidiabetic medications are effective (Hu, Manson et al. 2003). 
Insulin resistance is a key element in the pathogenesis of the metabolic syndrome and 
type II diabetes mellitus, both of which have reached epidemic proportions worldwide (Alberti 
and Zimmet 1998). Although the pathogenesis of type II diabetes remains poorly understood, 
most investigators agree on the following: 1) Insulin resistance, which can be defined as a state 
of reduced responsiveness to normal circulating levels of insulin, plays a major role in the 
development of type 2 diabetes. 2) Early in the disease, /3-cells secrete sufficient insulin to 
compensate for insulin resistance and maintain euglycemia. Ultimately, relative or absolute 
insulin deficiency supervenes, precipitating hyperglycemia and overt diabetes. /3-cell dysfunction 
is, therefore, a sine qua non of the diabetic state, but need not be the primary abnormality (Boden, 
2001 #103). 
1.2.5 Diabetic Complications 
Diabetic complications can be classified into acute and chronic complications, as 
described below. The acute complications include diabetic ketoacidosis, hyperosmolar non-
Ketotic coma, lactic acidosis, and hypoglycemia. Diabetic ketoacidosis and hyperosmolar non-
ketotic coma are related to insulin deficiency (Kelly, Howe et al. 2005). Hypoglycemia results 
from the treatment of diabetes, either with oral agents or insulin. Although hypoglycemia may 
occur in conjunction with oral hypoglycemic therapy, it is more common in patients treated with 
insulin. Lactic acidosis is usually associated with other factors that may be related to diabetes, 
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such as cardiovascular disease (acute myocardial infarction) associated with hypoxia and excess 
lactic acid production (Ueno and Shiotani 1999). 
The chronic complications include vision disorders (Retinopathy, Cataract, and 
Glaucoma), neuropathy, nephropathy, atherosclerosis (narrowing of the arteries), lower 
extremity foot ulcers and amputations, heart disease, infection, and oral/periodontal 
complications. 
1.2.5.1 Retinopathy 
Diabetic retinopathy is the leading cause of new cases of blindness in adults in the United States. 
Among all new cases of legal blindness in adults, 11 % are due to diabetic retinopathy, including 
12% at age 20-44 years, 19% at age 45-64 years, and 8% at ages ~65 years. Of people who are 
legally blind, 9% have diabetes as the cause. In the Wisconsin Epidemiologic Study of Diabetic 
Retinopathy (WESDR), about 97% of Type I, 80% of insulin-treated Type II, and 55% of Type 
II who were not treated with insulin had evidence of retinopathy by 15 years of diabetes (Vitale 
1998). The most severe stage, proliferative diabetic retinopathy, was present in 30% of Type I, 
10%-15% of insulin-treated Type II, and 5% of Type II not treated with insulin after 15 years of 
diabetes. The major risk factor for incidence and progression of diabetic retinopathy is 
hyperglycemia. Two other complications of diabetes, cataracts and glaucoma, can lead to visual 
loss. Senile lens changes measured by ophthalmic examination were found by the Framingham 
Eye Study in 63% of Type II, aged 50-64 years, and 78% of those aged 65-74 years (Hiller, 
Sperduto et al. 1988). Rates of cataract are often ~50% higher in Type II than in control persons. 
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1.2.5.2 Neuropathy 
Neuropathy is a common complication of Type I and Type II. In population-based studies, 30-
70% of patients were affected, depending on neuropathy criteria. In Rochester, MN, the 
prevalence was 60% for any neuropathy , 4 7% for distal polyneuropathy, 34% for carpal tunnel 
syndrome , and 5% for autonomic neuropathy (Dyck, Karnes et al. 1992; Dyck, Davies et al. 
1999). Most cases of distal polyneuropathy and carpal tunnel syndrome were subclinical or 
asymptomatic . In the diabetes control and complications trial, intensive treatment of diabetes 
with near-normalization of glycemia reduced the 5-year prevalence by 60%-70%, compared with 
the conventional treatment group (Keen 1994 ). 
1.2.5.3 N ephropathy 
Diabetes accounts for ~35% of all new cases of end-stage renal disease in the United States, and 
is the leading cause of new end-stage renal disease. Persons with diabetes comprise the fastest 
growing group of renal dialysis and transplant recipients. Diabetic nephropathy is the leading 
cause of kidney disease in patients starting renal replacement therapy, and affects approximately 
40% of type I and type II diabetic patients. It increases the risk of death, mainly from 
cardiovascular causes, and is defined by increased urinary albumin excretion in the absence of 
other renal diseases (Gross, de Azevedo et al. 2005). A large proportion of persons with diabetes 
have elevated urinary albumin excretion, with ~20%-30% having microalbuminuria and ~20%-
30% having macroalbuminuria (Gross, de Azevedo et al. 2005). Control of blood glucose can 
reduce the rate of progression of renal disease in diabetes. In the diabetes normoglycemic and 
complications trial, intensive insulin therapy was associated with a 39% reduced risk of 
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microalbuminuria, and a 54% reduced risk of macroalbuminuria (Keen 1994). Control of blood 
pressure also decreases the rate of progression of renal disease, and angiotensin-converting 
enzyme (ACE) inhibitors may be renoprotective, independent of their effects on blood pressure. 
Several studies have suggested that reduction of dietary protein may lower the rate of 
progression of renal disease (Casani, Bangstad et al. 2000; Gross, de Azevedo et al. 2005). Most 
studies of risk factors have been conducted on Type I, but little is known about the effectiveness 
of these treatment modalities on Type II. 
1.2.5.4 Atherosclerosis 
Lower extremity arterial disease is identified clinically by intermittent claudication and/or 
absence of peripheral pulses in the lower legs and feet, representing decreased arterial perfusion 
of the extremity. In population-based studies, pulse deficits were found in ~ 10% of diabetic 
subjects, absent foot pulses in ~20%-30%, and intermittent claudication in ~9%. In the National 
Health and Nutrition Examination Survey II, prevalence of pulse deficits in subjects with Type II 
was about twice that of subjects with normal glucose tolerance (Eck, Hackett-Renner et al. 
1992). In contrast to control subjects, heart disease in diabetes appears earlier in life, affects 
women almost as often as men, and is more often fatal (Bray and Bellanger 2006; Pi-Sunyer 
2007). The most common cause of death in adults with diabetes is coronary heart disease, and 
~50% of deaths of people with diabetes are due to ischemic heart disease (Takeda and Shimizu 
1994; Okeda 1996). The excessive risk of heart disease in diabetic versus control subjects has 
been found in numerous community-based studies (Bray and Bellanger 2006; Pi-Sunyer 2007). 
Endogenous and exogenous insulin and lack of glycemic control may act as cardiovascular 
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disease risk factors. Adults with diabetes are more likely than those without diabetes to have 
hypertension and dyslipidemia, but some of the increased risk of heart disease associated with 
diabetes appears to be independent of these factors (Bray and Bellanger 2006; Pi-Sunyer 2007). 
1.2.5.5 Infections 
Studies in clinic, community, and hospital populations indicate that diabetic subjects probably 
have a higher risk of some infections, including asymptomatic bacteriuria, lower extremity 
infections, reactivation tuberculosis in American Indians, infections in surgical wounds after 
sternotomy and total hip replacement, and group B streptococcal infection (Hartemann-Heurtier, 
Robert et al. 2004; Gulcelik, Kaya et al. 2005; Thuluvath 2005; Wieman 2005). Population-
based data support a probable higher mortality rate from influenza and pneumonia. Diabetes may 
possibly be associated with other infections, but appropriate studies have not been conducted. 
Local and systemic immunologic defects and autonomic and sensory neuropathy probably 
contribute to the increased propensity to infections (Cavanagh, Lipsky et al. 2005). 
1.2.5.6 Oral Complications 
Studies during the past 40 years have found that periodontal disease is more severe and occurs 
with higher frequency in diabetic patients. In one study, the prevalence of periodontal disease in 
Type I patients was 9 .8%, compared with 1. 7% in people without diabetes (Rylander, Ramberg 
et al.). The rate in the Type I patients increased from 0% at ages ::;1 0 years to 3 0% at ages ~ 9 
years (Onkamo, Vaananen et al. 1999). Prevalence of gingivitis was ~ 70% of those aged <19 
years, and ~98% of those aged ~9 years (Brown and Loe 1993). Periodontal attachment loss 
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was ~50% greater in Type I patients with retinopathy, compared with control patients, but was 
not elevated in Type II patients without retinopathy (Soskolne and Klinger 2001). These and 
other data indicate that poor glycemic control increases the extent and severity of periodontal 
disease in Type I. 
Few studies have dealt with Type II. In the Pima Indians, attachment loss and alveolar 
bone loss were more extensive than in control pimas (Genco and Loe 1993). Toothlessness was 
15 times more frequent in the diabetic than the control group, and the incidence of periodontal 
disease was 2.6 times higher (Loe and Genco). Reasons for the greater occurrence of periodontal 
destruction in diabetes are not clear. Studies of the periodontal flora find similar microorganisms 
in diabetic and control individuals, suggesting that alteration in the patient's responses to 
periodontal pathogens may account for the differences in periodontal destruction. 
1.2.5. 7 Wound Healing in Diabetics 
In recent years, a consensus has prevailed that the wound healing process in diabetes is affected, 
and may contribute to various clinical complications of diabetes such as the development of 
diabetic foot ulcers (Veves, Falanga et al. 2001 ). The normal course of wound healing in people 
with diabetes appears to be hindered by many factors, including specific metabolic deficiencies 
and impaired physiological responses (Boulton and Connor 1988; Pecoraro, Ahroni et al. 1991). 
Diabetes can result in the development of several complications, including diabetic foot 
problems that can potentially lead to lower limb amputation, as described earlier on page X. As 
many as 15% of the people with diabetes will develop foot ulceration and its related 
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complications (Reiber, 1996 #109). Abnormal wound healing in people with diabetes is well 
recognized (Jeffcoate, Price et al. 2004; Falanga 2005; Van 2005). However, the exact 
mechanism by which healing occurs is not known (Falanga 2005). 
A number of factors would appear to be involved. These factors include cellular features, 
such as retardation of closure, delayed contraction possibly because of retardation of the 
myofibroblast phenotype, effects on granulocytes, defects in chemotaxis, interference with 
collagen synthesis, effects on red blood cells, defective control of apoptotic cell death. However, 
cellular factors alone are not responsible for the delays in wound healing. Other factors also play 
a role which includes the altered metabolism of carbohydrates, fats, and proteins resulting from 
the absence or deficiency of insulin, hyperglycemia, leading to non-enzymatic glycosylation and 
free radical production. In a study conducted by Tervonen and his associates, results indicated 
that molar sites with bone loss of greater than fifteen percent were significantly higher (43.9%) 
in those with poorly controlled diabetes as compared to those with well-controlled diabetes 
(28.2%). The researchers concluded that periodontal support is significantly compromised earlier 
in the course of the disease for those in which Type I diabetes is poorly controlled. The 
researchers concluded that this situation may have been caused by altered healing capacity and 
inability to regenerate lost tissue, as a result of the diabetic condition (Tervonen, Karjalainen et 
al. 2000). 
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1.3 Apoptosis 
1.3.1 Definition and Introduction 
Apoptosis is defined as programmed cell death. Specifically, it is a form of cell death "in 
which a programmed sequence of events leads to the elimination of cells without releasing 
harmful substances into the surrounding area" (Huang 2002). In this process, cells disintegrate 
into membrane-bound particles. Afterwards, through, in the process of shedding (phagocytosis ), 
the cells are eliminated. As related to the morphology of dying cells, cell death is usually divided 
into two groups or categories: necrosis and apoptosis. In necrosis, the cell membrane degrades, 
and cellular contents are released into the extracellular matrix (McKenna, McGowan et al. 1998). 
"Necrosis is a pathological death of cells resulting from the irreversible damage that occurs" 
(Satchell, Gutmann et al. 2003). In cell death as a result of apoptosis, chromosomal DNA and 
nuclei concentrations of the cells are fragmented. 
"Apoptosis is a genetically modulated form of cell death, in which superfluous or 
abnormal cells are eliminated from an organism, ensuring normal development of multicellular 
organisms and maintenance of tissue homeostasis" (Huang, Wu et al. 2005). Apoptosis takes 
place in various cell types, and is triggered by a number of extracellular and intracellular signals 
(Hanahan and Weinberg 2000). An abnormal apoptotic mechanism is considered as the main 
contributor involved in a number of pathological diseases, ranging from cancer to 
neurodegeneration (Rodriguez-Nieto, Zhivotovsky et al. 2006). The molecular mechanisms 
underlying apoptotic cell death pointed to the presence of two biochemical markers of apoptosis, 
namely the activation of the caspases and the fragmentation of nuclear DNA into 
oligonucleosome-sized DNA fragments by apoptotic nucleases (Wyllie, Kerr et al. 1980; Patel, 
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Gores et al. 1996). Apoptosis primarily takes place through two discrete pathways: Extrinsic and 
intrinsic pathways of apoptosis. 
1.3.2 Extrinsic Pathway of Apoptosis 
Apoptosis may take place when specific transmembrane death receptors and their 
respective ligands initiate the extrinsic pathway, leading to the formation of a death receptor-
inducing signaling complex (DISC), including receptor, ligand, the adapter molecule F ADD. The 
cell surface receptor, Fas or CD95, is the most studied inducer of this pathway that is activated 
through binding to its ligand, FasL (Sheikh and Fomace 2000). Another important cell surface 
receptor is TNFRl , which , when activated by its ligand, TNF, stimulates the extrinsic pathway of 
apoptosis. Upon formation of the death receptor-inducing signaling complex, its downstream 
target , caspase 8, is activated, triggering a chain of events resulting in the activation of effector 
caspases such as caspase-3 , 6, and 7. Caspase-3, 6, and 7 are called executioner caspases , 
because they ultimately cause membrane proteolysis and cellular damage. 
The extrinsic pathway is triggered by death domain-containing receptors such as 
DRS/KILLER of the TRAIL family (Bums, Bernhard et al.; Wu, Bums et al. 1997). 
Furthermore, caspase-8 is an important initiator caspase of the death receptor pathway (Ding, 
McGill et al. 1998). 
1.3.3 Intrinsic Pathway of Apoptosis 
Apoptosis may also take place through an intrinsic pathway, which involves the 
depolarization of mitochondria , cytochrome-c release into the cytoplasm from the mitochondrial 
membrane system, formation of the apoptosome, and finally resulting in the activation of 
caspases (Gross , Yin et al. 1999). The pro- and anti-apoptotic Bcl-2 family proteins, which 
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regulate the intrinsic pathway, consist of three subclasses: The pro-survival proteins with strong 
homology to bcl-2, such as BclXl; the proapoptotic proteins, Bax and Bak, with structural 
similarity to Bcl-2; and the BH3-only proapoptotic proteins, namely, PUMA (Gross, McDonnell 
et al. 1999). 
Cellular stress results in the activation of the Bax gene of the Bcl-2 family via p53 
regulation (Herr and Debatin 2001). This Bax gene activation results in the release of 
cytochrome-c from the mitochondrial membrane, and final activation of caspase-3 and caspase-9 
(Cregan, MacLaurin et al. 1999). Bax-deficient mice exhibit accelerated tumor growth and 
substantial decrease in p53-mediated apoptosis. Accordingly, Bax can also mediate p53 
independent tumor suppression (Ryan, Phillips et al. 2001). 
p53, in response to various types of stress, up-regulates PUMA, a powerful mediator of 
cell death (Jeffers, Parganas et al. 2003). PUMA requires Bax for induction of apoptosis, and has 
been demonstrated to promote translocation and oligomerization of Bax, resulting in effective 
cell death; while Bax-deficient cells are resistant to PUMA-mediated apoptosis (Yu, Wang et al. 
2003). PUMA, upon induction, can couple the nuclear and cytoplasmic apoptotic function of p53 
by liberating p53 from the antiapoptotic BclXl in the cytoplasm; whereupon, freed p53 localizes 
to the mitochondria to promote apoptosis in a transcription-independent manner (Chipuk, 
Bouchier-Hayes et al. 2005). Activated p53 also suppresses the antiapoptotic Bcl-2 (Korsmeyer 
1992). 
1.3.4 Importance of Apoptosis 
As previously noted, the production and maintenance of enough fibroblasts that 
contribute to wound repair in the body are of great significance in those persons who have 
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diabetes. Studies showed that enhanced glycosylation of proteins, abnormal growth factor 
expression, decreased fibroblast numbers, or enhanced apoptosis may underlie the problem and 
become important contributors in the repair of wounds (Alikhani, Alikhani et al. 2005). 
Apoptosis is not only a key process in oral embryological development of the tooth, periodontal 
ligament, and supporting oral tissue; it also plays a major role in progression of oral disease, 
bone resorption, and wound healing (Darby, Bisucci et al. 1997; Satchell, Gutmann et al. 2003; 
He, Liu et al. 2004). Cell death comes about as a result of a coordinated action by gene products, 
as explained by Mullauer and his associates (Mullauer, Gruber et al. 2001). Activation of 
caspases plays a crucial role in the development of apoptosis . However, in addition to caspases, 
other components of the proteolytic machinery involve the cathepsins, calpains, and proteasomes 
that also mediate apoptosis. Non-caspase proteases can operate either downstream of caspase, 
and thus participate in the amplification of the proteolytic cascade; or they may operate upstream 
of caspases, thus triggering this proteolytic cascade (Grimm, Goldberg et al. 1996; Waterhouse, 
Finucane et al. 1998; Broker, Huisman et al. 2004). Apoptosis is significantly related to poor 
wound healing, and leads to diabetic complications that are quite debilitating (He, Liu et al. 
2004). In fact, impaired healing in the patient affects the resolution of chronic, as well as acute 
wounds. Especially in the United States, this has become a serious concern, according to 
Engelgau and his associates (Engelgau, Geiss et al. 2004 ). Hospitalization and even amputation 
of extremities can result from ulcerations brought about through the poor healing process in 
diabetic persons. 
As previously noted, the production and maintenance of enough fibroblasts that 
contribute to wound repair in the body is of great significance in those persons who have 
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diabetes. As reported by Herskind and his associates, impaired osseous healing is present in 
individuals suffering with type I diabetes (Herskind, Christensen et al. 1992). The researchers 
concluded that this impairment may be caused by reduced bone formation. The conclusions of 
Herskind et al. were supported by an earlier study conducted by Pietschmann, Schernthaner, and 
Woloszczuk , who found that serum osteocalcin levels were significantly lower in Type I diabetes 
patients as compared to others (Pietschmann, Schernthaner et al. 1988). The researchers also 
discovered a significant reduction in osteoblast functioning, in addition to a significant reduction 
in numbers. 
1.3.5 Apoptosis of Oral Tissue and Role in Endodontics 
Apoptosis is a major key process that occurs in every part of the body and functions in 
health and in disease. Specifically, apoptosis refers to the programmed death of cells and 
functions to obliterate scattered cells by fragmentation (Satchell, Gutmann et al. 2003). These 
fragments become membrane-bound particles that are then destroyed by other cells. In the 
mouth, the process of apoptosis brings about embryological growth of the tooth, oral tissue 
surrounding the tooth , and periodontal ligament which can subsequently develop into oral 
disease, bone resorption , inflammation , and immunological response, among other processes of a 
similar nature (McKenna, McGowan et al. 1998). The role of apoptosis in other oral tissue is not 
as clear. While it is known that the process is necessary to retain homeostasis in renewing tissues 
( e.g., skin, oral mucosa) , its role in oral epithelial cell differentiation is not yet completely 
understandable. The steps in the process in normal oral tissue need first be documented to serve 
as baseline information for further research. However, it is a well know fact that apoptosis is 
significantly involved in oral cavity disease mechanisms. Much research exists on the role of 
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apoptosis in periodontal disease (Satchell, Gutmann et al. 2003). It is know that the process takes 
place in periodontium cells as a normal part of turnover and remodeling. In addition, it is 
significantly involved in the regulation of age as pertains to some immune cells. Tonetti and his 
associates believe apoptosis also has a function in the maintenance of local immune homeostasis 
in inflamed gingival tissue (McGhee, Tonetti et al. 1998). In addition, increases in epithelial cell 
apoptosis in the periodontium of those with periodontal disease has been linked to increased 
inflammation. Apoptosis also functions to decrease granulation tissue during wound contraction, 
Myofibroblasts vanish when granulation tissue develops into a scar (Satchell, Gutmann et al. 
2003). 
The bacteria in the pulp canal space stimulate release of chemokines and cytokines that 
attract inflammatory cells in the site. The inflammatory reaction being a defense mechanism also 
leads to host tissue destruction (Kiss 2004). The presence of bacteria and their bacterial toxins, 
enzymes, and waste products in the periapical area was one of the major contributors to the 
breakdown of the host tissue (Bhattacharyya, Biswas et al. 2004; Rotstein and Simon 2004). 
Uncontrolled diabetes can play a critical role in the healing of a lesion of endodontic origin. 
Kohsaka et al. evaluated the changes in the periapical tissue of control and diabetic rats that had 
pulp exposures induced mechanically. They found that diabetics had severe inflammation in the 
apical periodontal ligament and delayed wound healing due to impaired bone and soft tissue 
reconstruction when compared to the control rats (Verhaeghe, Suiker et al. 1989; Kohsaka, 
Kumazawa et al. 1996). They also noticed large lesions in the periapical area in diabetic rats 
(Kohsaka , Kumazawa et al. 1996). In the pulp of the tooth, apoptosis is a part of normal 
homeostasis. However , it takes place less in the apical portions of the pulp as compared to the 
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occlusal and is mainly associated with the subodontoblastic region. The process becomes more 
noticeable after injury, especially during cavity preparation (Kitamura, Kimura et al. 2001). 
1.3.6 TNF-~ 
In response to bacterial products, TNF-a expression is induced by various cell types 
including keratinocytes, monocytes, macrophages, PMN s, and Langerhans cells (Liu, Bal et al. 
2006). Delayed wound healing in diabetics is attributed to decreased fibroblast numbers which in 
tum could possibly result from one of the following factors: aberrant growth factor expression, 
altered inflammatory responses, enhanced glycosylation of proteins or enhanced apoptosis. Type 
I diabetics have delayed bone healing which may be caused by reduced bone formation (Al-
Mashat, Kandru et al. 2006). Marked increase in the levels of tumor necrosis factor (TNF- a) a 
pleiotropic cytokine that plays an important role in immunity and inflammation is noticed in 
chronic illness. This increase in TNF- a contributes to cachexia, hemorrhage, necrosis, and in 
severe cases, death. Many diseases caused by immune disorders see an elevated TNF- a, which 
is directly associated with persistent inflammation and tissue destruction. The inflammatory 
events stimulated by TNF- a can lead to connective tissue destruction by the release of lytic 
enzymes produced by resident cells as well as by recruited inflammatory cells (Liu, Bal et al. 
2006). TNF-a is a monocyte-derived cytokine induces fibroblast apoptosis through the cytosolic 
and caspase-8-dependent pathway. TNF-a could be involved in the pathogenesis of endodontic 
lesions due to its ability to activate PMNs, to cause alterations in the endothelial cell function, 
induce the production of collagenase and PGE2 by fibroblasts (Nair 2004 ). In both periodontal 
and endodontic lesions, the infection stimulates an inflammatory cascade that culminates tissue 
destruction, once this infection spreads it initiates the formation of osteolytic lesion which is 
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thought to be from the induction of cytokines in particular TNF and IL-I (Graves and Cochran 
2003 ). TNF and IL-I stimulate osteoclast formation and activity. It has been indicated to play a 
significant role in bone loss as a potent inflammatory cytokine (Steeve, Marc et al. 2004). TNF-
a can affect the repair process, decreasing wound strength that may be due to decreased collage 
type I and type III expression. Inhibition or deletion of TNF- a generally enhances repair 
processes. Genetic ablation of TNF receptor- I improves wound healing by enhancing 
angiogenesis, collagen production, and re-epithelialization. Similarly, administration of TNF 
inhibitor in diabetic mice significantly increases collagen deposition (Liu, Bal et al. 2006). 
Diabetes is associated with excessive TNF- a expression which may result from overproduction 
by adipose tissue in type 2 diabetes, the effects of hyperglycemia and advanced glycation end 
products and an exaggerated or more persistent response to stimuli such as bacteria or wound 
healing. TNF- a over expression in diabetes is thought to contribute to several complications in 
diabetes, including retinopathy, nephropathy, and diabetes-enhanced periodontal disease. 
However diabetes-associated TNF- a over expression contributes to impaired wound healing has 
not been established. During development unwanted cells, are removed by apoptotic 
programmed cell death. However in disease enhanced apoptosis may occur inadvertently, 
aggravating damage that occurs during infection or interfering with healing (Liu, Bal et al. 
2006). 
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MATERIALS AND METHODS 
1.4 Animals Studies 
Seven- to eight-week-old db/db animals, along with their genetic normoglycemics, were 
purchased from Jackson Laboratory (Bar Harbor, Maine). The animal procedures undertaken 
were approved by the Institutional Animal Care and Use Committee at Boston University 
Medical Center. At the age of six to eight weeks, the db/db mice sample developed diabetes. The 
fasting levels of blood glucose of all db/db mice were recorded; the animals were considered to 
be diabetic if their fasting serum glucose levels were higher than 250 mg/dl for at least 20 days 
prior to experimentation. During the experimental period, the normoglycemic mice evidenced 
glucose levels of roughly 100-150 mg/dl, whereas the db/db mice showed levels between 400-
450 mg/dl. 
1.5 Traumatic Wound and Inoculation of Bacteria 
In order to identify the role of diabetes in wound healing, the animals were subjected to 
traumatic wounds, with bacterial inoculation between the midline of the scalp between the ears. 
Porphyromonas gingivalis was inoculated to stimulate tissue loss, as was suggested previously 
by Holt (Holt, Ebersole et al. 1988). A traumatic wound was created through inoculation of 
bacteria for studying the inflammatory response in wound healing in diabetes. The bacteria 
provoked bone and tissue loss, initiating the progression of periodontitis. Bacteria were cultured 
in broth and seeped at log phase growth during a six-hour process, in one percent 
paraformaldehyde. Next, the mice were anesthetized using ketamine (80mg/kg) and xylazine 
( 1 0mg/kg), 5x 108• The following step in the procedure was to inoculate the bacteria P. gingivalis 
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between the ears at the midline of the animal's scalp. An inflammatory response and damage to 
bone and tissue resulted from the inoculation, in addition to a healing reaction, which was 
expected. On the eighth day of the experiment, these reactions were identified, similar to the 
findings of He (He, Liu et al. 2004) and Liu (Liu, Desta et al. 2004). This day was selected 
because fibroblast apoptosis would peak at this point, and because it would show the greatest 
difference in apoptosis between diabetic and normoglycemic mice, according to Liu et al (Liu, 
Desta et al. 2004). From their study, the researchers concluded that diabetes altered the response 
to bacteria by enhancing fibroblast apoptosis. Also, according to the results of He, Liu and his 
associates (He, Liu et al. 2004), diabetes caused decreased osteoclastogenesis, reduced bone 
formation, and enhanced apoptosis of osteoblastic cells in bacteria-stimulated bone loss. 
1.6 RNA Profiling 
After confirming the diabetic state, the mice were killed eight days later in a CO2 
asphyxiation chamber, and the scalp was excised. Frozen fragments of samples were 
homogenized by mortar and pestle at -130°c. Total RNA was prepared from these samples using 
Trizol Reagent. All experimental protocols were approved by the Boston University Animal 
Institute Committee . Gene expression analysis of all RNA samples was performed by Affymetrix 
Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA). The GeneChip® Mouse Genome 
430A 2.0 Array is a single array that contains over 22,600 probe sets, representing transcripts 
and variants from over 14,000 well-characterized mouse genes. RNA was prepared from 
normoglycemic and db/db mice, using a trizol extraction, followed by cleanup using the RNeasy 
kit (Qiagen, CA, USA). To determine that the isolated RNA was not degraded, agarose gel-
electrophoresis was performed , followed by staining with ethidium bromide. OD readings 
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(A260/ A230) were also undertaken. The readings registered within an appropriate range of 1.9 to 
2.1. 
Two separate sets of microarrays were described. One focused on normoglycemic mice, 
and the other focused on the diabetic mice. The Harvard-Forsyth Collaborative Microarray Core 
(in Cambridge , MA) completed all the steps in the microarray probe preparation, as well as the 
hybridization and reading of fluorescent intensity. Each time point was replicated twice, making 
the data from each array truly independent biological replicates. 
1. 7 Data Analysis 
To measure the impact of diabetes and normoglycemic mice on wound healing, we 
looked at the mRNA levels of different functional group genes. Two software packages were 
used to perform these analyses. These included PathwayArchitect and ArrayAssist. For the 
analysis of these gene values we considered a minimum of two fold higher or lower change in 
the level of expression relative to the baseline was used as an arbitrary threshold. The genes 
identified were of a minimum increase of 1. 7 fold in each of the two arrays and at least two fold 
of the average of the two arrays. After the probe logarithmic intensity error normalization and 
basic filtering methods the genes which were 1. 7 fold up or down-regulated were further 
categorized in to functional categories. The genes were considered upregulated when the ratio 
between the diabetic and normoglycemic group was equal to or more than 1. 7 and the genes 
considered down-regulated when the ratio was less than or equal to 0.58, whereas the genes with 
intermediate fold change that fall between 1. 7 and 0.58 were considered no change. 
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RESULTS 
RNA expression profiling was carried out to determine the effect of diabetes on the 
global expression of genes, followed by gene ontology analysis to organize candidate genes 
functionally into biologically relevant categories by utilizing Pathway Architect and Array Assist 
software (Tables 1-7). As described above in the data analysis section, a conservative approach 
was undertaken to define an increase, a decrease, and no change in genes in each functional 
category. As a result of a data-mining process, a total of 221 apoptotic genes were found be 
directly or indirectly involved in the regulation of apoptosis. Of these, 3 were down-regulated 
and a total of 71 were enhanced by diabetes (Tables 1-4). Since apoptosis occurs when the 
balance between anti-apoptotic and pro-apoptotic genes is altered due to an external or internal 
stimulus, we determined the ratio of pro-apoptotic and anti-apoptotic genes altered by diabetes. It 
was noted that 63 of the 7 4 genes that showed a twofold increase were pro-apoptotic, while the 
remaining 11 genes were anti-apoptotic. It was thus concluded that diabetes had a significant 
impact that was definitely pro-apoptotic. 
To further gain a functional and mechanistic linkage, apoptotic genes were divided into 
previously annotated functional groups such as pro-apoptotic or anti-apoptotic, which included 
mitochondrial factors and caspases; intercellular mediators such as death-inducing ligands; 
receptors and intracellular mediators, which included death receptors and accessory molecules; 
and transcription factors (Tables 1-4). Apoptotic factors included mitochondrial factors as well 
as caspases. The diabetic group, when compared and normalized to the control group, showed 
that genes such as Casp9 increased 6.9 fold; Stk4 increased 5.6 fold; Ciasl increased 3.7 fold; 
Diablo increased 2.3 fold; and Casp3 increased 2.3 fold. Diabetes, however, also affected some 
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anti-apoptotic genes such as Birc7, which increased 6.5 fold; Bnip2, which increased 3.2 fold; 
Bcl2, which increased 3.1 fold; Birc3, which increased 2.4 fold; Api5, which increased 2.4 fold; 
and NOL3 , which increased 2.0 fold. Compared with the control group, the diabetic group 
showed increased TNF gene expression, which induces apoptosis, as diabetes inhibited apoptosis 
genes in the Bcl2 family. The pro-apoptotic genes TNF increased 2.9 fold; Fas increased 3.3 fold 
in the diabetic group. The anti-apoptotic genes that were up-regulated included Birc-3, Birc-4, 
Birc-7, Bcl-2, and Api-5. Intercellular mediators such as death-inducing ligands, including 
TNFSF8 , increased 6.4 fold; ILl 7 increased 4.8 fold; Tnfsfl0 increased 4.7 fold; Tnfsf7 
increased 2.9 fold; Nos 1 increased 2.9 fold; LT-a increased 2.6 fold; and anti-apoptotic gene 
TGF {3 l was down-regulated. 
Most of these genes in the "receptors and intracellular mediators" group showed no 
change, but some of the most important genes, like Fas, increased 3.3 fold; Tnfrsfl 1 b increased 
3.3 fold; Fadd increased 3.1 fold; Adrala increased 2.7 fold; Prkca increased 2.7 fold; Prkcz 
increased 2.6 fold; Tnfrsf9 increased 2.2 fold, and Apafl increased 2.0 fold. Transcription factor 
genes, namely Ddit3 increased 5.0 fold; Foxo3 increased 3.6 fold; E2f2 increased 3.2 fold; E2Fl 
increased 2.1 fold; Brcal increased 3.0 fold; Plagll increased 2.7 fold; and Plagl2 increased 2.3 
fold, whereas anti-apoptotic gene p53 was down-regulated by 0.4 fold. Our microarray data 
analysis suggests that diabetes affected several classes of genes involved in regulating apoptosis 
generally in a pro-apoptotic direction. 
After establishing the role of diabetes in altering apoptosis-related genes, we wanted to 
study the genes involved in wound healing and their expression as a function of time in 
normoglycemic mice. We divided differentially regulated genes into two functional subsets. Set 
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1 included healing, angiogenesis, and growth factors, and set 2 included matrix formation and 
immune response. In normal 5 day vs. normal O day, 18 genes were up-regulated belonging to 
the matrix formation category and none were down-regulated (Table 5). Some important 
collagen synthesis genes were up-regulated, including AMELX [ amelogenin ( amelogenesis 
imperfecta 1, X-linked)], which increased 2.8 fold; COLlAl (collagen type I a 1), which 
increased 1.9 fold; COL1A2 (collagen type I a 2), which increased 1.7 fold; COL3Al (collagen 
type III a 1), which increased 1.7 fold; COL5Al (collagen type Va 1), which increased 3.4 fold; 
COL8Al (collagen type VIII a 1), which increased 3.4 fold; COL9Al (collagen type IX a 1), 
which increased 1.9 fold; EMILINl ( elastin microfibril interfacer 1 ), which increased 6.9 fold; 
FBLNl (fibulin 1), which increased 2.4 fold; FBN2 [fibrillin 2 (Marfan syndrome)], which 
increased 2.7 fold; MATN4 (matrilin 4), which increased 3.2 fold; MFAP2 (microfibrillar-
associated protein 2), which increased 3.7 fold; PRELP (proline arginine-rich end leucine-rich 
repeat protein), which increased 2.5 fold; and MF AP3 (microfibrillar-associated protein 3), 
which increased 8.1 fold. Matrix metalloproteinase superfamily genes that regulate matrix 
degradation, such as MMP2, MMP7, and MMP9, showed no change, whereas MMP3 increased 
2.1 fold and MMP19 increased 3.5 fold, suggesting that these two genes can play a critical role 
in remodeling connective tissue. 
Five days was an important time point to see how healing, angiogenesis, and growth 
factor gene expression could play roles in the normal repair process. Liu., et al. (2004) reported 
that on day 5, much of the inflammation was reduced and tissue healing started. mRNA profiling 
was used to investigate genes that modulate healing and angiogenesis. When we looked at 
normoglycemic 5 day vs. normoglycemic O day. 44 genes were up-regulated belonging to the 
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healing, angiogenesis, and growth factor category, and none of them were down-regulated (Table 
6). Out of these, some important genes such as BMP 1 (bone morphogenetic protein 1 ), which 
increased 2.0 fold; BMP7 (bone morphogenetic protein 7), which increased 4.3 fold; BMP15 
(bone morphogenetic protein 15), which increased 2.4 fold; CSFl [ colony stimulating factor 1 
(macrophage)], which increased 1.9 fold; Elk3 (ELK3, a member of the ETS oncogene family), 
which increased 3.4 fold; FBSl (fibrosin 1), which increased 3.4 fold; FGB (fibrinogen, B 
polypeptide), which increased 4.7 fold; FGF6 (fibroblast growth factor 6), which increased 3.2 
fold; FGFl 1 (fibroblast growth factor 11), which increased 2.7 fold; FGF13 (fibroblast growth 
factor 13), which increased 1.9 fold; FGFl 6 (fibroblast growth factor 16), which increased 2.6 
fold; GJA4 [gap junction protein, a 4, 37kDa (connexin 37)], which increased 2.0 fold; GNA13 
[guanine nucleotide binding protein (G protein), a 13], which increased 2.3 fold; GRN 
(granulin), which increased 1.8 fold; IGF2 (insulin-like growth factor II precursor), which 
increased 2.3 fold; IGFBP4 (insulin-like growth factor binding protein 4), which increased 2.2 
fold; IL12A (interleukin-12 a chain precursor), which increased 2.0 fold; IL1F6 (interleukin 1 
family, member 6), which increased 3.0 fold; MAP,2K7 (mitogen-activated protein kinase kinase 
7), which increased 2.4 fold; MAPK14 (mitogen-activated protein kinase 14), which increased 
2.0 fold; OGFR ( opioid growth factor receptor), which increased 1.9 fold; PECAMl 
[platelet/endothelial cell adhesion molecule (CD31 antigen)], which increased 2.8 fold; PTPRJ 
(protein tyrosine phosphatase, receptor type, J), which increased 2.1 fold; SERPINE 1 [ serine ( or 
cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1 ), member 
1], which increased 2.7 fold; TBXl (T-box 1), which increased 1.8 fold; and TGFBl 
(transforming growth factor {3 l precursor), which increased 2.9 fold. As mentioned above, the 
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genes that play an important role in angiogenesis-namely GJa 4, ELK, and T-box 1 (TBXl), 
the bone morphogenetic protein family genes (BMPs), and the fibroblast growth factor family 
genes were up-regulated. 
Normoglycemic mice sometimes show the ability to enhance the inflammatory response 
to bacteria at the site of injury. Elevated levels of inflammation are regulated by immune defense 
genes and play a significant role in wound healing. On 5 day vs. 0 day, 72 genes were up-
regulated belonging to immune response and none were down-regulated (Table 7). Some of the 
most important genes that were up-regulated include CCL2 [ chemokine (C-C motif) ligand 2], 
which increased 3.0 fold; CCL3 [chemokine (C-C motif) ligand 3], which increased 4.1 fold; 
CCL6 [ chemokine (C-C motif) ligand 6], which increased 1.8 fold; CXCL9 [ chemokine (C-X-C 
motif) ligand 9], which increased 2.1 fold; PRKR (protein kinase, interferon-inducible double 
stranded RNA dependent), which increased 2.3 fold; CCL4 [ chemokine (C-C motif) ligand 4], 
which increased 2.4 fold; CCRl [chemokine (C-C motif) receptor 1], which increased 2.0 fold; 
TLR8 (toll-like receptor 8), which increased 2.0 fold; CXCLl0 [chemokine (C-X-C motif) 
ligand 10], which increased 1.7 fold; CXCL16 [chemokine (C-X-C motif) ligand 16], which 
increased 1.7 fold; CTSC (cathepsin C), which increased 1.8 fold; CTSS (cathepsin S), which 
increased 2.3 fold; CXCL2 [ chemokine (C-X-C motif) ligand 2], which increased 4.2 fold; 
CXCL5 [chemokine (C-X-C motif) ligand 5], which increased 14.3 fold; IL16 [interleukin 16 
(lymphocyte chemoattractant factor)], which increased 2.1 fold; IRF2 (interferon regulatory 
factor 2), which increased 3.2 fold; LCP2 (lymphocyte cytosolic protein 2), which increased 2.1 
fold; LTB (lymphotoxin ~), which increased 2.6 fold; STATSA (signal transducer and activator 
of transcription 5A), which increased 2.8 fold; TNFSFl 1 [tumor necrosis factor (ligand) 
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superfamily, member 11], which increased 2.5 fold; TLRl (toll-like receptor 1), which increased 
3.8 fold; TLR2 (toll-like receptor 2), which increased 2.4 fold; TNFRSF9 (tumor necrosis factor 
receptor superfamily, member 9), which increased 2.2 fold; TLR4 (toll-like receptor 4), which 
increased 2.2 fold; TLR 7 (toll-like receptor 7), which increased 2.3 fold; and TLR8 (toll-like 
receptor 8), which increased 4.6 fold. 
Liu., et al. (2004) reported that at 8 days matrix formation and healing is almost 
complete. Microarray analysis investigated whether angiogenesis and growth factor gene 
regulation was significantly modulated during healing at the 8 day time point. On 8 day vs. 0 
day, 14 genes were upregulated belonging to healing , angiogenesis and growth factors category 
(Table 6). None of them were down-regulated. Some of the important genes such as BMP7 (bone 
morphogenetic protein 7 precursor), which increased 1. 7 fold; CDC42 ( cell division cycle 42 
homolog), which increased 1.7 fold; FGF16 (fibroblast growth factor 16), which increased 2.0 
fold; FGF5 (fibroblast growth factor 5), which increased 2.6 fold; GNA13 [guanine nucleotide 
binding protein (G protein), a 13] ), which increased 4.3 fold; IFNG (interferon gamma 
precursor)), which increased 2.6 fold; IL1F6 (interleukin 1 family, member 6) ), which increased 
2.4 fold; ILIF9 (interleukin 1 family, member 9), which increased 1.9 fold; ILlRN (interleukin-I 
receptor antagonist secreted form precursor), which increased 3.2 fold and MTPN (myotrophin), 
which increased 2.0 fold. Surprisingly some of the important angiogenesis genes thought to play 
a significant role in wound healing showed no change. These included gap junction protein, aS 
(GJa. 5), GJa 4, plasminogen (PLG), frizzled homolog 5 (FZD5), endothelial PAS domain 
protein 1 (EPASl), connective tissue growth factor (CTGF), endoglin precursor (ENG).Vascular 
endothelial growth factor receptor 2 (VEGFR-2), vascular endothelial growth factor B (VEGFB) 
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an important angiogenic factors that stimulate the migration of endothelial cells and T-box 1 
(TBXl) showed no change. Many bone morphogenetic protein family genes (BMP's), fibroblast 
growth factor family genes, platelet-derived growth factor family, nerve growth factor genes 
showed no change. Identification of genes with differential expression collectively provides a 
quantitative view of a specific subset of cellular genes playing a role wound healing (Stetter, 
Schurmann et al. 2004 ). 
Liu., et al. (2004) noticed that new bone formation started at day 5 in normal mice but at 
8 days the amount of new bone formation is much higher signifying healing is advanced at this 
time point (Liu, Desta et al. 2004 ). On 8 day vs. 0 day, 14 genes were upregulated belonging to 
matrix formation category and none were down regulated (Table 5). Several genes involved in 
collagen synthesis were upregulated such as COLlAl (collagen type I a.1), which increased 1.7 
fold; COL1A2 (collagen type I a 2), which increased 2.5 fold; COL3Al (collagen type III a 1), 
which increased 1.9 fold; COL5Al (collagen type V a 1), which increased 2.6 fold; COL8Al 
(collagen type VIII a 1), which increased 1.7 fold; COL9Al (collagen type IX a 1), which 
increased 1.9 fold; EMILINl ( elastin microfibril interfacer 1 ), which increased 2.3 fold; FBLNl 
(fibulin 1), which increased 1.6 fold; FBNl (fibrillin 1), which increased 1.7 fold; FNl 
(fibronectin 1), which increased 4.8 fold; HAPLNl (hyaluronan and proteoglycan link protein 1), 
which increased 5.4 fold and MF AP3 (microfibrillar-associated protein 3), which increased 6.1 
fold. However, most of the MMP superfamily genes such as mmp2, Mmp3, Mmp7 and Mmp9 
that regulate matrix formation showed no change. 
On 8 day vs. 0 day, 41 genes involved in mediating immune responses were upregulated 
and none were down regulated (Table 7). Some of the most important genes that were 
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upregulated include CCL2 [ chemokine (C-C motif) ligand 2], which increased 3.7 fold; CCL3 
[chemokine (C-C motif) ligand 3], which increased 2.8 fold; CCL6 [chemokine (C-C motif) 
ligand 6], which increased 2.5 fold; CXCL9 [ chemokine (C-X-C motif) ligand 9], which 
increased 5.6 fold; PRKR (protein kinase, interferon-inducible double stranded RNA dependent), 
which increased 2.4 fold; TLR8 (toll-like receptor 8), which increased 3.6 fold; CTSC (cathepsin 
C), which increased 2.1 fold; CTSS ( cathepsin S), which increased 2.2 fold; CXCL2 [ chemokine 
(C-X-C motif) ligand 2], which increased 2.4 fold; CXCL9 [ chemokine (C-X-C motif) ligand 9], 
which increased 5.6 fold; LCP2 (lymphocyte cytosolic protein 2), which increased 2.3 fold; 
TLRl (toll-like receptor 1), which increased 3.8 fold; TLR2 (toll-like receptor 2), which 
increased 2.0 fold; TNFRSF9 (tumor necrosis factor receptor superfamily, member 9), which 
increased 2.2 fold; TLR3 (toll-like receptor 3), which increased 1.8 fold; TLR8 (toll-like receptor 
8), which increased 4.6 fold. Some other important chemokines and interleukins such as CCL4 
[chemokine (C-C motif) ligand 4], CCRl [chemokine (C-C motif) receptor 1], CXCLl0 
[chemokine (C-X-C motif) ligand 10], CXCL16 [chemokine (C-X-C motif) ligand 16] and IL16 
[interleukin 16 (lymphocyte chemoattractant factor)] showed no change. The majority of 
cytokines and chemokines genes that were upregulated can in tum be regulated by NF-KB 
pathway which triggers inflammatory and immune processes important in pathogenesis of 
periodontal destruction (Milward, Chapple et al. 2007). 
The infilteration of wound by polymorphonuclear leukocytes and 
monocytes/macrophages occurs at early phases of injury and in the later stages plays a role in 
healing. At 8 days monocytes and macrophages stimulate growth factor production that regulates 
wound healing (Singer and Clark 1999). On 8 day vs. 5 days, 48 genes were upregulated and 9 
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were down-regulated belonging to healing, angiogenesis, growth factors category (Table 6). Out 
of these some important genes such as CDC42 ( cell division cycle 42 homo log), which increased 
2.9 fold; Elk3 (ELK3, member of ETS oncogene family), which increased 2.5 fold; GNA13 
[guanine nucleotide binding protein (G protein), a 13], which increased 3.7 fold; IFNG 
(interferon 'Y precursor), which increased 3.4 fold; IL1F9 (interleukin 1 family, member 9), 
which increased 1.8 fold; ILlRN (interleukin-I receptor antagonist secreted form precursor), 
which increased 2.3 fold; MAP2K7 (mitogen-activated protein kinase kinase 7), which increased 
3.7 fold; and MTPN (myotrophin), which increased 2.4 fold. Most of the bone morphogenetic 
protein family genes (BMP's), fibroblast growth factor family genes, platelet-derived growth 
factor family genes showed no change between 8 vs. 5 day. 
Healing on day 8 was then compared to 5 days, 15 genes were upregulated belonging to 
matrix formation category and 10 of them showed no change (Table 5). Some of the important 
collagen synthesis genes were upregulated in normoglycemic 8 days when compared to 
normoglycemic 5 day such as COL1A2 (collagen type I a 2), which increased 2.3 fold; COL3Al 
(collagen type III a 1), which increased 4.9 fold; COL5Al (collagen type V a 1), which 
increased 6.6 fold; COL8Al ( collagen type VIII a 1 ), which increased 8.5 fold; EMILINl 
(elastin microfibril interfacer 1), which increased 8.7 fold; FNl (fibronectin 1), which increased 
2.2 fold; HAPLNl (hyaluronan and proteoglycan link protein 1), which increased 2.4 fold; 
MATN4 (matrilin 4), which increased 3.2 fold; MFAP2 (microfibrillar-associated protein 2), 
which increased 2.2 fold; MF AP3 (microfibrillar-associated protein 3), which increased 1.8 fold 
and PRELP (proline arginine-rich end leucine-rich repeat protein), which increased 12.8 fold. 
However several genes that play an important role in regulating matrix formation like AMELX 
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(amelogenesis imperfecta 1, X-linked), BGN (biglycan), COLlAl, COL9Al (collagen type IX a 
1), FBLNI (fibulin 1), FBN2 [fibrillin 2 (Marfan syndrome)] showed no change. 
Inflammation along with tissue destruction could influence the healing rate, so the 
mRNA expression of pro-inflammatory cytokines/chemokines was analyzed. On 8 day vs. 5 
days, 28 genes were upregulated belonging to immune response; none down regulated (Table 7). 
Most of the cytokine ligands and receptors genes showed no change on 8 day compared to 5 day. 
Cytokine genes that were upregulated include CCL2 [ chemokine (C-C motif) ligand 2], which 
increased 1.8 fold; CCL3 [chemokine (C-C motif) ligand 3], which increased 1.7 fold; CCL6 
[ chemokine (C-C motif) ligand 6], which increased 2.6 fold, CCL8 [ chemokine (C-C motif) 
ligand 8], which increased 1.7 fold, CCL9 [chemokine (C-C motif) ligand 9], which increased 
2.0 fold, IGJ (immunoglobulin J polypeptide, linker protein for immunoglobulin a and {3 
polypeptides), which increased 3.6 fold, IL6ST (interleukin 6 signal transducer), which increased 
1.9 fold; IL 7R (interleukin 7 receptor), which increased 2.3 fold; PFC (properdin P factor, 
complement), which increased 1.8 fold; PRKR (protein kinase, interferon-inducible double 
stranded RNA dependent), which increased 3.9; TLR3 (toll-like receptor 3), which increased 2.8 
fold; TLR4 (toll-like receptor 4), which increased 2.4 fold and TLR8 (toll-like receptor 8), 
which increased 1.7 fold. 
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DISCUSSION 
The current study identifies that diabetes is responsible for altering the expression of 
apoptotic genes belonging to various categories, such as pro-apoptotic or anti-apoptotic factors 
(mitochondrial factors and caspases), intercellular mediators (death-inducing ligands), receptors 
and intracellular mediators ( death receptors and accessory molecules), and transcription factors. 
In this study, out of the 276 apoptotic genes identified, 63 out of 71 were up-regulated, proving 
that diabetes increases the expression of pro-apoptotic genes that play an important role in 
delayed wound healing. It has been shown previously that diabetes increases apoptosis in the 
target tissue, playing a pivotal role in the diabetic group, resulting in delayed remodeling and 
healing (Rai, Suryabhan et al. 2005). Apoptosis is modulated by a number of genes and is tightly 
controlled by a fine balance between pro-apoptotic and anti-apoptotic gene products. We show 
that diabetes has an impact on genes that regulate apoptosis signaling pathways, resulting in the 
up-regulation ofligands such as TNF-a, Fas, FasL receptors, and effector caspases such as casp3 
and casp9. Apaf-1 plays a role in mitochondrial pathway and is also up-regulated in the diabetic 
group. Anti-apoptotic genes belonging to the Birc family were up-regulated in the diabetic 
group, along with a high number of apoptotic fibroblasts in the diabetic group, suggesting that 
survival and cell death are based on the induction of pro-apoptotic and anti-apoptotic genes that 
delay wound healing. However, the gene expression of transforming growth factor-/31 (TGF-/31) 
was significantly down-regulated in diabetics compared with controls. Some of the apoptosis 
regulators that were anti-apoptotic were up-regulated; these anti-apoptotic genes included Birc7, 
which increased 6.5 fold; Bnip2, which increased 3.2 fold; Bcl2, which increased 3.1 fold; Birc3, 
which increased 2.4 fold; Api5, which increased 2.4 fold; and NOL3, which increased 2.0 fold. 
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Dermal wound healing is a highly complex molecular and cellular process that involves 
angiogenesis, proliferation, migration , hemostasis, inflammation, and remodeling. This process 
is also accompanied by growth factors and cytokines released at the injury site. Dermal 
fibroblasts play a role in the formation of tissue at the injury site (Martin 1997; Norrby 1997; 
Singer and Clark 1999; Chodorowska and Rogus-Skorupska 2004). Al mashat et al. showed that 
the fibroblast's apoptosis was much higher in diabetic mice when compared to matched controls 
(P < 0.01), and the impact of increased apoptosis and enhanced caspase activity in diabetic mice 
was examined by treating the diabetic group with specific caspase inhibitor. Caspase inhibition 
significantly reduced the rate of fibroblast apoptosis in the diabetic group when compared to 
control animals (n = 6) and had an overall favorable effect on the healing process characterized 
by increased fibroblast density, collagen 1, III expression, and the formation of new healing 
tissues in diabetic mice. Histomorphometric analysis demonstrated that there was a 1.4 fold 
increase in bone formation in the diabetic mice treated with a caspase blocker compared to a 
vehicle alone. The effect of caspase-inhibitor treatment was significant but not as impressive as 
the improvement observed in soft connective tissue formation. He et al. (2004) showed the .utility 
of the calvarial model to study the impact of diabetes and apoptosis on new bone formation. As 
in this model, bacterial challenge induced a cycle of bone formation followed by repair (He, Liu 
et al. 2004). 
Caspase3 is the primary effector caspase through which TNF-a induces apoptosis. During 
the early destructive phase of bacterial inoculation, casp3 activity was induced in the diabetic 
animals as well as in the controls. In general, there was a close relationship between casp3 
activity and the level of fibroblast apoptosis, suggesting that casp3 is an important effector 
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caspase through which infection by P. gingivalis results in programmed cell death (Liu, Bal et al. 
2006). Among the list of up-regulated genes, the role of casp3 in apoptosis has been a major 
element and has shown to be up-regulated at both the protein and mRNA level (Grutter 2000; 
Philchenkov 2004). Thus, the increase in the mRNA level of casp3 as indicated by microarray 
and real-time PCR corresponded with the above study. 
After identifying that diabetes significantly affects the genes involved in apoptosis and 
delays wound healing, the specific patterns of genes involved in wound healing in normal mice 
as a function of time, with "0" being the time of injury, "5day" being the time of peak healing, 
and "8day" being almost healed. We divided the differentially expressed genes into two 
categories: category 1 included healing, angiogenesis, and growth factors, and category 2 
included matrix formation and immune response in normoglycemic mice. The majority of genes 
belonging to the bone morphogenetic protein (BMP) family and fibroblast growth factor (FGF) 
family were up-regulated from 0 to 5 days and showed no change from 5 to 8 days, signifying 
that BMP plays an important role in the early phases of healing, which are characterized by new 
bone induction. Bone morphogenetic protein (BMP) is a procollagen C-proteinase, which 
initiates and promotes chondrogenesis and osteogenesis (Johannesburg 1998). There are different 
types of BMPs that are presently known members of the BMP superfamily that play a significant 
role in the remodeling of bone and other connective tissues (Lieberman, Daluiski et al. 2002). 
The most important feature of bone morphogenetic protein is the formation of new bone. FGFs 
are a class of genes responsible for fibroblast proliferation and migration, which contributes to 
wound healing. These factors also play an important role in wound healing by modulating the 
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expression of matrix, growth factors, angiogenesis, and healing genes (Braun, auf dem Keller et 
al. 2004). These findings suggest that matrix synthesis starts in the early phase. 
Our data show that genes active in early phases of healing involve fibroblast 
proliferation. Wound healing is characterized by the orderly behavior of various cellular and 
extracellular components (Hodde and Johnson 2007). In our study, we observed that genes 
responsible for collagen synthesis and remodeling were up-regulated at 5 days and showed 
increased expression at 8 days. Collagen type IV, named collagen of basal lamina, is mainly 
distributed in various basement membranes and plays a key role in cellular proliferation, 
differentiation, and vascular formation (Chen, Fu et al. 2003). Collagen V can block blood 
coagulation and takes part in skin formation (Chen, Fu et al. 2003). Fibronectin showed 
increased expression at all phases of healing (Moore and Haugen 2007). Collagen XI showed no 
change at all phases of healing, which is closely related to the aggregation of other collagens and 
interaction with other molecules (Famdale, Sixma et al. 2004). Most of the MMPs increased only 
at 5 days, suggesting that they play an important role in earlier phase in the transition from 
inflammation to remodeling. They play a significant role in leukocyte extravasation (Vaday, 
Franitza et al.). Some of them have the ability to modulate inflammatory and immune responses 
by processing chemokines. Matrix metalloproteinases (MMPs) play a critical role in reorganizing 
the matrix formation at the injury site, which helps in connective tissue remodeling and wound 
healing (Hartenstein, Dittrich et al. 2006). MMP3 was up-regulated 2.9 fold at day 5 but showed 
no change at day 8. Hartenstein et al. reported that MMP3 produced by dermal fibroblasts helps 
in the formation of granulation tissue and that MMPl is up-regulated in the early stages of injury 
but gradually decreases with the re-epithelialization that happens at the later stage, especially in 
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the case of dermal wound healing (Hartenstein, Dittrich et al. 2006). Hecht, J. Kuhl., et al. 
showed that MMP 19 is up-regulated in skin wounds at day 7, suggesting a role in repair and 
wound healing. Jansen , P. L., et al. showed that high levels of MMP2 that are detected after 
injury are crucial for dermal wound healing because they play a role in angiogenesis, 
inflammation, and fibrosis (Jansen, Rosch et al. 2007). However, in our study, MMP2, MMP7, 
and MMP9 showed no change in all three healing phases-i.e. , 0 day, 5 day, and 8 day. 
Chemokines are the potent angiogenic factors that play a role in stimulating endothelial 
cell chemotaxis (Rossi and Zlotnik 2000). Chemokines belonging to the CXC (C-X-C motif) 
ligand group act as pro-inflammatory factors (Rosenkilde and Schwartz 2004). Several cytokines 
affect chemokine expression, such as TNF-a, IL-1, IL-6, IL-12 and IL-18. The transcription of 
genes that are known to be involved in the mechanisms of wound healing and fibrogenesis, 
which play a role in inflammation, are up-regulated by cytokines (Zhang, Yu et al. 2004). Our 
data showed that many of the cytokine ligands and receptors were up-regulated at 5 days and had 
a moderate increase at 8 days. All of these play significant roles in normal homeostasis, wound 
healing, fibrosis including lymphoid development, and the migration of cellular elements (Rossi 
and Zlotnik 2000). 
Studies have shown that signal transduction in response to several Gram-positive bacteria 
and peptidoglycan is mediated by toll-like receptors (TLRs) (Takeda and Akira 2005). One of 
the main functions of TLRs is to act as sensors for bacterial infection and to initiate the 
proinflammatory response (Rakoff-Nahoum, Paglino et al. 2004). TLR signaling express 
production of several cytokines such as IL-6, IL-8, IL-12, TNF-a, and other cytokines that are 
important for the immune defense response. The suppression of TLRs can result in the host 
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becoming hyporesponsive to the immune response and can contribute to cytokine imbalance 
(Bals and Hiemstra 2004). Our data showed that toll-like receptors such as TLR2, TLR4, TLR7, 
and TLR8 are up-regulated at 5 days, suggesting a role in initiating the inflammatory and 
immune defense response and showing that the host response and inflammation are more 
elevated at 5 days (Takeda, Kaisho et al. 2003). TLR4 helps in the production of 
proinflammatory cytokines. 
Neoangiogenesis is an important step in wound healing that takes place by the formation 
of granulation tissue, which is mediated by angiogenesis (Babic, Chen et al. 1999). Vascular 
endothelial growth factor (VEGF) plays a role in dermal wound healing by inducing growth 
factors that are important for tissue repair and thus by activating bone marrow-derived cells to 
speed up the repair process at the injury site (Galiano, Tepper et al. 2004). VEGF, which was up-
regulated at 5 days and showed no change at 8 days and is a critical gene that plays a role in 
angiogenesis and wound healing as described above. Our results also indicate that platelet-
derived growth factor chain B precursor (PDGFB), is increased at 5 days. Platelet-derived 
growth factor at the site of injury by platelets causes increased fibroblast production and, in tum, 
directly or indirectly enhances extracellular matrix formation (Rajkumar, Shiwen et al. 2006). 
Many other growth factors and cytokines released by fibroblasts, endothelial cells, macrophages, 
and platelets are needed for the process of wound healing (Ferrara 2000). Our data showed that 
most of the growth factors and cytokines are up-regulated at 5 days but there is only a moderate 
increase at 8 days. 
In this study, cDNA microarray analysis and data mining with bioinformatics software 
(ArrayAssist and Pathway Architect) proved to be an efficient tool for identifying the impact of 
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diabetes on various genes belonging to apoptosis that play a significant role in wound healing. 
Evidently, healing is impaired as a result of diabetes-enhanced apoptosis, which can be partially 
explained by diabetes-increased expression of pro-apoptotic genes. In conclusion, microarray 
analysis provides a powerful tool for investigating different gene expression between groups. 
Our data on the gene expression of matrix, growth factors, angiogenesis, healing, inflammatory 
cytokines, and apoptosis validate the use of this technology for future studies of gene expression 
to demonstrate normal and abnormal wound healing. 
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Tables 
Table 1: list of transcription factors affected by diabetes at 8 days vs. normoglycemics 
Name Array 1 Array 2 Mean fold difference 
Pro-apoptoti c 
Ddit3 6.4 3.6 5.0 
Foxo3 3.9 3.2 3.6 
Mybl2 1.8 4.7 3.2 
E2f2 2.4 4.1 3.2 
Brcal 2.2 3.7 3.0 
Plagl 1 2.4 3.0 2.7 
Plag12 2.3 2.3 2.3 
Mitf 1.8 2.4 2.1 
E2Fl 2.4 1.8 2.1 
Anti-apoptotic 
Nkx3-1 2.3 6.2 4.2 
TP53 0.4 0.3 0.4 
No change 
LMXlA 2.5 1.4 1.9 
TP73 1.4 1.9 1.7 
MBD4 1.2 2.0 1.6 
FOXOl 1.5 1.6 1.6 
PAX7 1.8 1.2 1.5 
REL 1.1 1.9 1.5 
MYC 1.3 1.2 1.3 
BTG2 1.2 1.2 1.2 
MYCN 1.2 1.1 1.2 
TFDPl 1.2 1.1 1.2 
TIALl 1.2 1.1 1.2 
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TP73L 1.1 1.0 1.1 
BCL6 1.0 1.2 1.1 
HDAC3 1.0 1.2 1.1 
STATl 1.1 1.0 1.1 
MKLl 1.0 1.0 1.0 
JUN 1.0 1.0 1.0 
NFKBIA 1.0 1.0 1.0 
AATF 0.9 1.1 1.0 
ATF5 0.9 0.9 0.9 
45 
Table 2: list of lntercellular signaling factors affected by diabetes at 8 days vs. 
normoglycemics 
Name Array 1 Array 2 Mean fold difference 
Pro-apoptotic 
TNFSF8 5.3 7.5 6.4 
Ill 7 2.7 6.8 4.8 
Sppl 4.8 4.8 4.8 
Tnfsfl0 3.9 5.5 4.7 
Grap2 2.6 5.4 4.0 
INS 2.3 3.8 3.1 
Tnfsf7 2.3 3.5 2.9 
Tnf 2.4 3.3 2.9 
Nosl 2.7 2.7 2.7 
LT-a 1.8 3.4 2.6 
Bdnf 2.4 2.5 2.5 
Angptl4 2.0 2.2 2.1 
Inhba 1.9 2.3 2.1 
Anti-apoptoti c 
TGFBl 0.3 0.6 0.5 
No change 
PLG 0.8 6 3.4 
ILIA 1.4 2.9 2.2 
DEDD 1.8 1.6 1.7 
ILlB 1.4 1.8 1.6 
TNFSF4 1.4 1.6 1.5 
TRADD 1.5 1.5 1.5 
TNFSF12 1.3 1.5 1.4 
CCL2 1.4 1.3 1.4 
IL18 1.2 1.3 1.3 
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RABEPl 1.2 1.3 1.3 
ILl0 1.1 1.3 1.2 
INHA 1.1 1.2 1.2 
FASLG 1.2 1.1 1.2 
VEGF 0.9 1.3 1.1 
IGFl 0.8 1.1 1.0 
VDACl 0.9 1.0 1.0 
PGLYRPl 0.6 1.0 0.8 
NGFB 0.2 0.9 0.6 
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Table 3: list of Intracellular signaling factors affected by diabetes at 8 days vs. 
normoglycemics 
Name Array 1 Array 2 Mean fold difference 
Pro-apoptotic 
Tnfrsfl0b 2.7 14.4 8.6 
Psenl 4.4 7.6 6.0 
Ikbkg 5.5 3.8 4.7 
Traf6 2.6 5.7 4.1 
Mapk14 3.6 3.2 3.4 
Notchl 2.9 3.8 3.3 
Fas 3.7 2.9 3.3 
Tnfrsfl lb 2.4 4.2 3.3 
Ptpn13 1.7 4.5 3.1 
Fadd 2.7 3.4 3.1 
Igflr 2.2 3.5 2.8 
Adrala 1.8 3.7 2.7 
Prkca 2.2 3.2 2.7 
Prkcz 2.9 2.4 2.7 
Tnfrsf9 3.0 2.2 2.6 
Mapk8 2.9 2.2 2.5 
Map2k2 2.4 2.6 2.5 
Map2k7 2.4 2.4 2.4 
Tnfrsflb 1.8 2.9 2.4 
Apafl 1.7 2.7 2.2 
Mapk9 2.1 2.3 2.2 
Siva 2.4 1.8 2.1 
Tnfrsf5 2.3 1.8 2.0 
No change 
NOS2A 1.6 6.1 3.9 
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TNFRSF12A 1.6 5.1 3.4 
F2 1.4 3.0 2.2 
MAPKl0 1.4 2.5 2.0 
EDAR 0.7 2.5 1.6 
CXCR4 1.4 1.7 1.6 
FAS 1.4 1.6 1.5 
TNFRSF4 1.4 1.6 1.5 
TNFRl 1.5 1.5 1.5 
TNFRSFlA 1.5 1.5 1.5 
CRADD 1.0 1.9 1.5 
ADORAl 0.8 2.1 1.5 
MAP2K6 1.6 1.3 1.5 
RHOB 1.4 1.5 1.5 
ABLl 1.2 1.5 1.4 
CD5L 1.1 1.6 1.4 
ITGB3BP 1.3 1.4 1.4 
MAPKK4 1.5 1.2 1.4 
ROCKl 1.3 1.3 1.3 
MALTl 1.4 1.2 1.3 
LTBR 1.2 1.3 1.3 
TNFRSF7 0.9 1.6 1.3 
TRAF3 1.2 1.3 1.3 
MAPKl 1.3 1.1 1.2 
MAPK3 1.1 1.3 1.2 
NGFR 1.5 0.9 1.2 
RAF-1 1.2 1.2 1.2 
TNFRSF25 1.3 0.9 1.1 
YWHAH 1.1 1.1 1.1 
MAP2Kl 1.1 1.0 1.1 
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BTK 1.2 0.9 1.1 
MAP3K5 0.9 1.1 1.0 
TRAF2 1.0 0.8 0.9 
GADD45B 0.9 0.9 0.9 
CDC42BPA 0.8 0.9 0.9 
TNFRSF21 0.6 1.0 0.8 
MAP2K4 0.7 0.9 0.8 
TRAF5 0.7 0.9 0.8 
MAP2K3 0.6 0.7 0.7 
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Table 4: list of direct intracellular regulators of apoptosis affected by diabetes at 8 days vs. 
normoglycemics 
Name Array 1 Array 2 Mean fold difference 
Pro-apoptoti c 
Dlgap3 6.1 7.2 6.7 
Casp9 7.1 5.5 6.3 
Stk4 3.8 7.5 5.6 
Ciasl 5.2 4.9 5.0 
Jmy 4.1 4.4 4.2 
Diablo 2.6 4.8 3.7 
Wwox 2.8 3.5 3.2 
Cdknla 2.7 3.3 3.0 
Dapk3 3.0 2.6 2.8 
Trim35 2.0 3.5 2.8 
Cflar 2.4 3.0 2.7 
Bcl211 2.3 3.1 2.7 
Bcl211 l 3.0 2.3 2.6 
Casp3 2.2 2.4 2.3 
Bcl2110 1.8 2.5 2.2 
Card4 2.0 2.1 2.0 
Tial 1.7 2.2 2.0 
BOK 2.2 1.7 2.0 
Anti-apoptotic 
Birc7 6.9 6.2 6.5 
Bnip2 2.9 3.5 3.2 
Bcl2 2.7 3.5 3.1 
Birc3 2.1 2.7 2.4 
Api5 2.8 2.0 2.4 
Son 2.1 1.9 2.0 
5 1 
NOL3 1.7 2.2 2.0 
Birc4 0.3 0.4 0.4 
No change 
ATM 1.5 2.2 1.9 
Bcl2ala 1.9 1.8 1.9 
Bircla 1.6 2.1 1.9 
BBC3 2.3 1.3 1.8 
AVEN 1.7 1.8 1.8 
CIDEB 2.2 1.2 1.7 
TNFAIP3 1.7 1.6 1.7 
Bid3 1.5 1.7 1.6 
BIRC2 1.7 1.5 1.6 
BNIP3 1.5 1.7 1.6 
CARD6 1.6 1.6 1.6 
CASP12 1.6 1.6 1.6 
HD 1.5 1.7 1.6 
HRK 1.5 1.7 1.6 
BAG3 1.6 1.4 1.5 
RIPK2 1.4 1.6 1.5 
RIPK3 1.2 1.8 1.5 
PDCD2 1.5 1.4 1.5 
PDCD5 1.5 1.4 1.5 
BCLl0 1.4 1.4 1.4 
DPF2 1.4 1.4 1.4 
BAG4 1.3 1.4 1.4 
BFAR 1.4 1.3 1.4 
CASPI 1 1.3 1.4 1.4 
CASP4 1.3 1.4 1.4 
DAP3 1.3 1.4 1.4 
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TAXlBPl 1.3 1.4 1.4 
BAGI 1.3 1.3 1.3 
PDCD8 1.1 1.5 1.3 
PTEN 1.3 1.3 1.3 
RNF7 1.3 1.3 1.3 
DAP 1.2 1.4 1.3 
PDCD6 1.2 1.4 1.3 
BNIP3L 1.3 1.2 1.3 
CTNNBLl 1.1 1.4 1.3 
CULl 1.2 1.3 1.3 
BBP 1.3 1.1 1.2 
CASPI 1.1 1.3 1.2 
STK17B 1.3 1.1 1.2 
CYCS 1.2 1.2 1.2 
NME6 1.5 0.9 1.2 
RAFI 1.2 1.2 1.2 
ASC 1.2 1.1 1.2 
BID 1.0 1.3 1.2 
BIRC5 1.0 1.3 1.2 
CASP8AP2 1.0 1.3 1.2 
CBX4 1.2 1.1 1.2 
FASTK 1.3 1.0 1.2 
PMAIPl 1.1 1.2 1.2 
PYCARD 1.2 1.1 1.2 
CASP2 1.1 1.1 1.1 
DAPKl 1.1 1.1 1.1 
DFFA 0.9 1.3 1.1 
GPXl 1.1 1.1 1.1 
NGFRAPl 1.0 1.2 1.1 
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SCOTIN 1.1 1.1 1.1 
CARDl0 1.0 1.1 1.1 
MCL-1 1.0 1.1 1.1 
PERP 1.1 1.0 1.1 
BAX 0.9 1.1 1.0 
BIRCl 0.9 1.1 1.0 
Bircle 0.9 1.1 1.0 
CARD14 0.8 1.2 1.0 
NDUFA13 0.9 1.0 1.0 
CASP8 0.8 1.0 0.9 
CASP7 0.9 0.8 0.9 
BAD 0.9 0.7 0.8 
CASP14 0.8 0.8 0.8 
DADl 0.8 0.8 0.8 
CASP6 0.6 0.6 0.6 
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Table 5: Matrix genes altered during the course of healing in normal animals 
Name Sd/Od Mean 8d/Od Mean 8d/5d Mean 
AMELX 2.8 N.C N.C 
BGN 2.5 1.7 N.C 
COLlAl 1.9 1.7 N.C 
COL1A2 1.7 2.5 2.3 
COL24Al N.C 1.8 1.7 
COL3Al 1.7 1.9 4.9 
COL5Al 3.4 2.6 6.6 
COL5A2 N.C 1.8 5.5 
COL5A3 2.1 1.6 N.C 
COL8Al 3.4 1.7 8.5 
COL9Al N.C 1.9 N .C 
EFEMP2 2.2 N.C N.C 
EMILINl 6.9 2.3 8.7 
FBLNl 2.4 1.6 N.C 
FBNl N.C 1.7 2.8 
FBN2 2.7 N.C N.C 
FNl 2.9 4.8 2.2 
HAPLNl N.C 5.4 2.4 
MATN4 3.2 N.C 0.4 
MFAP2 3.7 N.C 2.2 
MFAP3 8.1 6.1 1.8 
Mmpl0 N.C 0.2 N.C 
Mmpll 2.5 N.C 0.5 
Mmp12 N .C 2.0 3.0 
Mmp14 1.8 N.C N.C 
Mmp15 N.C N.C N.C 
Mmp16 N.C N.C N.C 
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Mmp19 3.5 N.C N.C 
Mmpla N.C 0.4 0.5 
Mmplb 3.2 N.C N.C 
Mmp2 N.C N.C N.C 
Mmp24 N.C N.C 2.9 
Mmp3 2.1 N.C N.C 
Mmp7 N.C N.C N.C 
Mmp9 N.C N.C N.C 
PRELP 2.5 N.C 12.8 
TFPI2 N.C 1.8 2.0 
WNT2 N.C 1.6 N.C 
WNT7B 3.2 N.C 2.7 
WNT9B 2.4 N.C N.C 
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Table 6: Healing, vascularity and growth genes altered during the course of healing in 
normal animals 
Name Sd/Od Mean 8d/Od Mean 8d/5d Mean 
AMH 1.7 N.C N.C 
BMPI 2.0 N.C N.C 
BMPI0 3.4 N.C N.C 
BMP15 2.4 N.C 0.5 
BMP7 4.3 1.7 N.C 
BMP8B 2.8 N.C 0.5 
CDC42 N.C 1.7 2.9 
COPEB N.C 5.4 N.C 
CRHR2 2.5 N.C N.C 
CSFl 1.9 N.C N.C 
CXCLl 3.1 N.C N.C 
Elk3 3.4 N.C 2.5 
ENG 2.1 N.C N.C 
ESRl 3.5 N.C N.C 
ESR2 3.6 N.C 0.3 
FBSl 3.4 N.C N.C 
FOB 4.7 N.C 0.1 
FGFll 2.7 N.C 4.1 
FGF13 1.9 N.C N.C 
FGF14 2.2 N.C N.C 
FGF16 2.6 2.0 N.C 
FGF17 2.0 N.C 3.3 
FGF5 4.0 2.6 N.C 
FGF6 3.2 N.C 0.5 
GJA4 2.0 N.C N.C 
GKNl 3.4 N.C N.C 
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GMFG 2.2 N.C 5.8 
GNA13 2.3 4.3 3.7 
GRN 1.8 N.C 2.3 
IFNG N.C 2.6 3.4 
IGF2 2.3 N.C 0.5 
IGFBP4 2.2 N.C 2.8 
IL12A 2.0 N.C 0.5 
IL1F6 3.0 2.4 N.C 
IL1F9 N.C 1.9 1.8 
ILlRN N.C 3.2 2.3 
MAP2K7 2.4 N.C 3.7 
MAPK14 2.0 N.C N.C 
MMP19 3.9 N.C N.C 
MTPN N.C 2.0 2.4 
NOV 2.0 2.1 2.2 
OGFR 1.9 N.C N.C 
PDGFB 1.8 N.C 2.4 
PECAMl 2.8 N.C N.C 
PGF 3.0 N.C 0.5 
PPAP2B N.C 2.4 2.9 
PTPRJ 2.1 N.C 2.1 
SERPINEI 2.7 N.C 0.5 
SOCSI 4.1 N.C N.C 
SOCS3 1.8 N.C N.C 
SYT7 1.8 N.C N.C 
TBXI 1.8 N.C N.C 
TGFBI 2.9 N.C 0.4 
TRO 2.2 N.C N.C 
VEGF 1.8 N.C N.C 
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WISPl 
WISP2 
XRN2 
1.8 
2.7 
N.C 
59 
N.C 
N.C 
2.8 
N.C 
N.C 
3.6 
Table 7: Immune response genes altered during the course of healing in normal animals 
Name 5d/0d Mean 8d/0d Mean 8d/5d Mean 
AFP 3.0 N.C N.C 
ATP6V0A2 3.1 N.C 3.0 
ClQG 1.9 2.0 N.C 
CIR 2.1 N.C N.C 
CCL12 4.1 2.4 N.C 
CCL2 3.0 3.7 1.8 
CCL25 2.2 N.C N.C 
CCL3 4.1 2.8 1.7 
CCL4 2.9 N.C N.C 
CCL6 1.8 2.5 2.2 
CCL8 N.C 1.7 1.7 
CCL9 N.C 2.6 2.0 
CCRl 2.0 N.C N.C 
CD164 2.7 N.C N.C 
CD6 4.4 N.C N.C 
CD79B 4.4 3.9 N.C 
CSF2 2.3 N.C N.C 
CTSC 1.8 2.1 N.C 
CTSS 2.3 2.2 N.C 
CXCLl0 1.7 N.C N.C 
CXCL16 1.7 N.C N.C 
CXCL2 4.2 2.4 N.C 
CXCL5 14.3 6.6 N.C 
CXCL9 2.1 5.6 4.9 
CYSLTR2 3.3 N.C N.C 
EDA 2.3 N.C 1.9 
FCERlA 2.0 N.C N.C 
60 
FCERlG 2.1 2.1 N.C 
FCGR2B 2.9 2.6 2.2 
G1P2 4.1 2.1 N.C 
GCNT2 5.0 3.5 2.1 
GPSM3 1.7 N.C N.C 
GTPBPl 1.8 N.C 2.5 
H2-Q10 3.2 N.C N.C 
ICSBPl 6.1 1.8 N.C 
Ifi203 2.6 3.4 2.7 
IFITl 2.2 2.0 N.C 
IFIT2 2.6 1.9 N.C 
IGJ N.C 2.0 3.6 
IL16 2.1 N.C N.C 
IL18RAP 3.6 N.C N.C 
IL1F6 3.0 N.C N.C 
ILlRN 2.2 N.C 2.1 
IL2RG 1.7 N.C N.C 
IL6ST N.C 2.8 1.9 
IL7R N.C 1.9 2.3 
IRF2 3.2 N.C N.C 
LCP2 2.1 2.3 N.C 
LSTl 3.4 3.2 N.C 
LTB 2.6 N.C N.C 
LY75 1.8 N.C N.C 
LY96 3.2 2.4 N.C 
NFIL3 2.1 N.C N.C 
OAS3 4.3 3.0 N.C 
Oasl2 2.3 2.2 N.C 
OPRMl 3.8 N.C N.C 
61 
PFC 2.5 2.3 1.8 
PLSCRl 2.0 N.C N.C 
PRKR 2.3 2.4 3.9 
PVRLl 2.2 N.C 2.1 
RAGl 3.1 N.C N.C 
SAMHDl N.C 1.8 N.C 
SEMA3C N.C 2.2 2.5 
SEMA4D 2.9 2.3 1.7 
STAT5A 2.8 N.C N.C 
TAPBP 4.8 2.4 N.C 
TCF12 2.6 2.3 3.2 
TLRl 3.8 3.8 N.C 
TLR2 2.4 2.0 N.C 
TLR3 N.C 1.8 2.8 
TLR4 2.2 N.C 2.4 
TLR7 2.3 N.C N.C 
TLR8 4.6 3.6 1.7 
TNFRSFlB 2.7 1.9 N.C 
TNFRSF9 2.2 N.C 3.9 
TNFSFl 1 2.5 N.C N.C 
VAVl 2.5 N.C N.C 
VTN 2.5 N.C 2.8 
XBPl 1.9 N.C 2.5 
ZAP70 1.8 N.C N.C 
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